Zanamivir-<wbr/><sup>13</sup>C,<sup>15</sup>N<sub>2</sub>

Zanamivir-13C,15N2

CAT N°: 30733
Price:

642.00 545.70

Zanamivir-13C,15N2 is intended for use as an internal standard for the quantification of zanamivir (Item No. 15123) by GC- or LC-MS. Zanamivir is a sialic acid analog that inhibits neuraminidase release of newly replicated influenza virus particles.{24439} It has been shown to selectively inhibit the growth of influenza A and B viruses in plaque reduction assays with IC50 values ranging from 5 to 14 nM and to directly inhibit influenza A and B virus neuraminidases with IC50 values ranging from 0.6 to 7.9 nM in vitro. Intranasal zanamivir administration at 0.4 mg/kg twice daily reduces mortality and viral titers in lung homogenates of mice infected with influenza.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 5-(acetylamino)-4-[(amino-15N-imino-15N-methyl-13C)amino]-2,6-anhydro-3,4,5-trideoxy-D-glycero-D-ido-non-2-enonic acid
  • Correlated keywords
    • GG 167 GG167 GR 121167X GR121167X 121167 X GR121167 Relenza
  • Product Overview:
    Zanamivir-13C,15N2 is intended for use as an internal standard for the quantification of zanamivir (Item No. 15123) by GC- or LC-MS. Zanamivir is a sialic acid analog that inhibits neuraminidase release of newly replicated influenza virus particles.{24439} It has been shown to selectively inhibit the growth of influenza A and B viruses in plaque reduction assays with IC50 values ranging from 5 to 14 nM and to directly inhibit influenza A and B virus neuraminidases with IC50 values ranging from 0.6 to 7.9 nM in vitro. Intranasal zanamivir administration at 0.4 mg/kg twice daily reduces mortality and viral titers in lung homogenates of mice infected with influenza.

We also advise you